Gene therapy for adenosine deaminase deficiency
- PMID: 10774451
- DOI: 10.1146/annurev.med.51.1.33
Gene therapy for adenosine deaminase deficiency
Abstract
The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (d) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.
Similar articles
-
[Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].Med Wieku Rozwoj. 2003 Jan-Mar;7(1):27-34. Med Wieku Rozwoj. 2003. PMID: 13130167 Review. Polish.
-
Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.Hum Gene Ther. 1993 Aug;4(4):521-7. doi: 10.1089/hum.1993.4.4-521. Hum Gene Ther. 1993. PMID: 7691188
-
Gene therapy for hematopoietic and immune disorders.Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S55-8. Bone Marrow Transplant. 1996. PMID: 8971410 Review.
-
Bone marrow gene therapy for adenosine deaminase deficiency.Immunodeficiency. 1993;4(1-4):335-45. Immunodeficiency. 1993. PMID: 7909479 Review.
-
Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.Blood. 2012 Nov 1;120(18):3677-87. doi: 10.1182/blood-2012-02-408591. Epub 2012 Jul 25. Blood. 2012. PMID: 22833548 Free PMC article.
Cited by
-
Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.Antimicrob Agents Chemother. 2003 Feb;47(2):501-8. doi: 10.1128/AAC.47.2.501-508.2003. Antimicrob Agents Chemother. 2003. PMID: 12543650 Free PMC article.
-
Molecular mechanism of transforming growth factor beta-mediated cell-cycle modulation in primary human CD34(+) progenitors.Blood. 2002 Jan 15;99(2):499-506. doi: 10.1182/blood.v99.2.499. Blood. 2002. PMID: 11781230 Free PMC article.
-
Hematopoietic stem cell gene therapy.Int J Hematol. 2002 Apr;75(3):228-36. doi: 10.1007/BF02982035. Int J Hematol. 2002. PMID: 11999349 Review.
-
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.J Immunol. 2005 Dec 1;175(11):7226-34. doi: 10.4049/jimmunol.175.11.7226. J Immunol. 2005. PMID: 16301627 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
